川芎嗪对脑梗塞患者脑脊液及血浆中一氧化氮含量的影响  

Effect of Ligustrazine on Nitric Oxide Contents in Cerebrospinal Fluid and Plasma of Patients with Cerebral Infarction

作　　者：李德洋[1] 石义亭[1] 陈玉萍[1] 李茹[1] 戴锋 

机构地区：[1]山东省滕州市中心人民医院,山东277500

出　　处：《中国中西医结合杂志》1998年第6期342-344,共3页Chinese Journal of Integrated Traditional and Western Medicine

摘　　要：目的 :探讨一氧化氮 (NO)在缺血性脑损伤中的意义及川芎嗪对其影响。方法 :采用Griess法测定了 2 0名对照者和 62例动脉粥样硬化性血栓性脑梗塞患者 (川芎嗪组和普通组 )治疗前后脑脊液 (CSF)、血浆中NO的含量。结果 :治疗前患者CSF中NO含量为重型 >中型 >轻型 >对照组 (P <0 0 5 ) ,并与脑梗塞灶大小呈正相关 (P <0 0 1 ) ,血浆NO含量与对照组无显著性差异 (P >0 0 5 ) ,但有随病情加重而下降的趋势。治疗后川芎嗪组疗效和血浆NO含量均显著高于普通组 (P <0 0 5 ) ,两组CSF中NO含量与对照组比较均无显著性差异 (P >0 0 5 )。结论 :脑组织产生过量的NO和血浆NO的不足参与了缺血性脑损伤的过程。川芎嗪可选择性地升高血浆中NO含量。Objective: To probe into the significance of Nitric Oxide (NO) in ischemic cerebral damage and effect of ligustrazine on it. Methods: The NO contents in cerebrospinal fluid (CSF) and plasma of 20 controls and 62 patients with arteriosclerotic thrombotic cerebral infarction (ligustrazine group and common treatment group) were determined with Griess method before and after treatment. Results: The NO content in CSF before treatment was higher in severe type, it was higher than that in moderate type, and than that in mild type, again higher than that in control group (all P<0 05) and was positively correlated with the size of infarction (P<0 01). There was no significant difference between the plasma NO content of patients and that of control group (P>0 05), but there was a trend that plasma NO content decreased as the patient's condition worsened. After treatment, the curative effect and plasma NO content of ligustrazine group were both markedly higher than those of common treatment group (P<0.05). There were no significant differences between CSF NO contents of the two groups, respectivley, and that of control group (P>0 05). Conclusions: Excessive NO produced in brain tissue and insufficient plasma NO participate the course of ischemic brain damage. Ligustrazine could increase the contents of plasma NO selectively.

关 键 词：川芎嗪 脑梗塞 一氧化氮 脑脊液 血浆 

分 类 号：R277.733.3[医药卫生—中医学] R285.5